Melphalan in combination with glucocorticoid steroids has been an important first-line treatment option for multiple myeloma (MM) for over 40 years, but response rates have been only 50-60%, with less than 5% complete remissions (CRs). More intensive combinations of chemotherapy such as ...
multiple myelomaClick on the option below that best describes youI am newly diagnosed and not eligible for a transplant I have received an autologous hematopoietic stem cell transplant I have relapsed after my first therapy Learn about REVLIMID Please see full Prescribing Information, including ...
multiple myeloma Click on the option below that best describes you I am newly diagnosed and not eligible for a transplantI have received an autologous hematopoietic stem cell transplantI have relapsed after my first therapy Learn about REVLIMID ...
REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM (multiple myeloma) who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients ab...
Learn more about REVLIMID®, a treatment option for multiple myeloma. See safety info and BOXED WARNINGS on fetal and hem tox & blood clots.
Selinexor is a first-in-class selective inhibitor of nuclear export that provides an additional therapeutic option for those with triple-refractory disease.36Selinexor has been studied in patients with quad- and penta-refractory disease because of their exposure to, and having become refractory to the...
cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM...
A therapeutic option for relapsed/refractory myeloma includes histone deacetylase inhibition. Various histone deacetylase inhibitors, including the newly approved panobinostat, are currently under evaluation in this setting. Panobinostat for multiple myeloma is used in combination with other potent therapeutic ...
that fixed-duration treatment may be effective in those who remain in remission at 1 year highlighting the potential for an extended treatment-free period which could soon be an emerging trend in myeloma. While it seems to be an attractive option, these data need to be validated in a larger...
There are plateaus on the curve, especially for those who had 1 prior line of therapy.3,6,8 For the right patient, lenalidomide/tafasitamab is a very good option and can give you some durable remissions, and these patients can stay in remission for quite a bit of time. It’s just [...